Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458906 | 1.00 | ACHE (0.51) | ACHETDP1TGM2EPHX2ERN1 | |
| SCHEMBL15809690 | 0.93 | ACHE (0.46) | ACHETDP1TGM2ERN1 | |
| SCHEMBL3676772 | 0.93 | TGM2 (0.46) | ACHETGM2EPHX2ERN1EPHX1 | |
| SCHEMBL15109209 | 0.87 | ALDH1A1 (0.46) | ACHETGM2EPHX2ERN1EPHX1 | |
| SCHEMBL2006530 | 0.85 | CHRNB2 (0.42) | ACHEERN1 | |
| SCHEMBL8769221 | 0.84 | EPHX1 (0.59) | ACHEEPHX2EPHX1 | |
| SCHEMBL6332791 | 0.84 | EPHX1 (0.59) | ACHEEPHX2EPHX1 | |
| SCHEMBL6332081 | 0.84 | EPHX1 (0.59) | ACHEEPHX2EPHX1 | |
| SCHEMBL8769159 | 0.84 | EPHX1 (0.59) | ACHEEPHX2EPHX1 | |
| SCHEMBL14328774 | 0.84 | EPHX1 (0.59) | ACHEEPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350563-B | Polymer capable of being assembled with protein and hydrophobic small molecule medicine and preparation method thereof | 至微(深圳)医学科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119350563-A | Polymer capable of being assembled with protein and hydrophobic small molecule medicine and preparation method thereof | 至微(深圳)医学科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118909145-A | Modified hydroxypropyl methyl cellulose, preparation method thereof and application thereof in mortar | 陕西惠诺施新材料科技有限公司 | 2024-11-08 | — | — | CN | claimed |
| EP-4366778-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | Bright Peak Therapeutics AG (CH) | 2024-05-15 | — | — | EP | claimed |
| CN-117615793-A | Antibody conjugates and their preparation | 明峰治疗股份公司 | 2024-02-27 | — | — | CN | claimed |
| WO-2023281481-A1 | ANTIBODY CONJUGATES AND MANUFACTURE THEREOF | BRIGHT PEAK THERAPEUTICS (CH) | 2023-01-12 | — | — | WO | claimed |
| CN-109912733-A | A method of polarity EP rubbers is prepared using new catalyst | 宁波高新区诠宝绶新材料科技有限公司 | 2019-06-21 | — | — | CN | claimed |
| CN-108976323-A | A method of polarity EP rubbers is prepared using new catalyst | 宁波高新区诠宝绶新材料科技有限公司 | 2018-12-11 | — | — | CN | claimed |
| CN-108977594-A | A kind of preparation method of amphoteric resin tanning agent | 宁波高新区诠宝绶新材料科技有限公司 | 2018-12-11 | — | — | CN | claimed |
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12383631-B2 | Immune antigen specific IL-18 immunocytokines and uses thereof | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-08-12 | — | — | US | disclosed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250197467-A1 | ACTIVATABLE IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-06-19 | — | — | US | disclosed |
| US-20250186597-A1 | TARGETED IMMUNE ACTIVATION WITH IL-18 IMMUNOCYTOKINES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2025-06-12 | — | — | US | disclosed |
| US-20130315822-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8361438-B2 | N-alkoxyamide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120328514-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2451776-A2 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005322-A2 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20090252676-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | PDCD1LG2, PDCD1, IL2 | ACHE 4878/4885TDP1 775/4885TGM2 2081/4885 |
| US-20250197467-A1 | ACTIVATABLE IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, IL2, IL36G | ACHE 3608/4885TDP1 3353/4885TGM2 783/4885 |
| US-20130315822-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ACHE 499/4885TDP1 97/4885TGM2 598/4885 |
| US-12383631-B2 | Immune antigen specific IL-18 immunocytokines and uses thereof | IL18, CD74, IL2 | ACHE 4750/4885TDP1 4327/4885TGM2 989/4885 |
| US-20250186597-A1 | TARGETED IMMUNE ACTIVATION WITH IL-18 IMMUNOCYTOKINES | ICOS, IL18, IL2 | ACHE 4835/4885TDP1 3410/4885TGM2 1771/4885 |
| US-20120328514-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ACHE 499/4885TDP1 97/4885TGM2 598/4885 |
| US-20090252676-A1 | N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS | TNNT2, UACA, ELANE | ACHE 499/4885TDP1 97/4885TGM2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.